Search Results

The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.

Filter your results:

Types

Topics

283 Results Found

Measuring the Correlation between Cost, Quality, and Outcomes in Healthcare

Advisory
Executive Summary Today’s healthcare environment is rapidly changing.

FGI Seeking Comments on Proposed Changes to the Guidelines for Design and Construction

The Facility Guidelines Institute (FGI) has issued a call for public comments on proposed updates to the 2026 edition of the FGI Guidelines.

Managing Water Safety for Construction Tool

This tool leverages existing core infection control risk assessment (ICRA) principles to establish a framework for water safety management during health care construction and renovation projects.

Advocacy Alert: Pressure relationship between operating rooms and other areas

Action Alert
Executive Summary ASHE has heard reports of surveyors issuing findings regarding the pressure relationship of operating rooms (ORs) and sterile storage rooms and the restricted areas of o

AHA Comments on IRS' Elective Payment of Applicable Credit Proposed Rule

The IRA, through the transferability provisions under Section 6418 and, in particular, the elective direct pay provisions of Section 6417, has provided new opportunities for the healthcare sector to engage in important clean energy initiatives.

AHA Letter of Support for the Drug Shortage Prevention Act of 2023

The Drug Shortage Prevention Act would require manufacturers to notify the Food and Drug Administration (FDA) of increased demand of covered drugs. The AHA believes the requirement that manufacturers notify the FDA of increased demand for critical drugs will be an integral tool for shoring up the supply chain.

AHA Letter of Support for the Rolling Active Pharmaceutical Ingredient and Drug, or RAPID, Reserve Act of 2023

Pharmaceutical shortages and supply chain failures can have a devastating impact on patients. The RAPID Reserve Act would establish a program to improve supply chain resiliency for critical generic drug products, ensuring adequate supply is available even in the event of a shortage.

AHA Letter of Support for the Pharmaceutical Supply Chain Risk Assessment Act of 2023

The Pharmaceutical Supply Chain Risk Assessment Act of 2023 would require a comprehensive risk assessment of the entire U.S. pharmaceutical supply chain. This overarching project will help provide critical information necessary to mitigate and prevent drug supply shortages.

AHA Letter of Support for the Mapping America's Pharmaceutical Supply Chain, or MAPS, Act of 2023

Hospitals and health systems share concern about chronic and increasing drug shortages that have serious consequences for patient safety, quality of care and access to therapies. Addressing drug shortages is complex and costly to hospitals and health systems in terms of staff time and other resources required to manage the shortages.
Public

FTC Urged to Extend Comment Period for Draft Merger Guidelines

The AHA joins the U.S. Chamber of Commerce and other organizations in urging the Federal Trade Commission to extend for at least 60 days the comment period for their draft guidance revising how they review mergers and acquisitions to determine compliance with federal antitrust laws.